期刊
JOURNAL OF INTERNAL MEDICINE
卷 273, 期 2, 页码 128-137出版社
WILEY
DOI: 10.1111/joim.12018
关键词
anti-angiogenic therapy; hypoxia; tumour invasion; tumour metastasis; tumour stroma; VEGF
资金
- European Union [ERC-StG-281830]
- MinEco-Spain [SAF2009-08375, RTICC-RD2006-0092]
- AGAUR-Generalitat [SGR681]
Moserle L, Casanovas O (Catalan Institute of Oncology - IDIBELL, Spain). Anti-angiogenesis and metastasis: a tumour and stromal cell alliance (Review). J Intern Med 2013; 273: 128-137. Tumour progression requires the activation of a tumour and stromal cell-driven angiogenic programme, and the targeting of this process demonstrates an impact on tumour growth and progression. The results of preclinical studies have demonstrated a proinvasive/metastatic effect of antiangiogenic treatments with recent evidence supporting a contribution of the stroma to tumour aggressiveness and the short-term effects of antivascular endothelial growth factor therapy. Furthermore, hypoxia-dependent and -independent factors are considered as driving forces for tumour cell escape by altering both the tumour cells themselves and the stroma. This tumourstromal cell alliance should be taken into consideration for the development of innovative therapeutic options targeting both tumour components to improve clinical benefits for cancer patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据